Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma. Issue 4 (12th March 2011)
- Record Type:
- Journal Article
- Title:
- Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma. Issue 4 (12th March 2011)
- Main Title:
- Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma
- Authors:
- Gardie, Betty
Remenieras, Audrey
Kattygnarath, Darouna
Bombled, Johny
Lefèvre, Sandrine
Perrier-Trudova, Victoria
Rustin, Pierre
Barrois, Michel
Slama, Abdelhamid
Avril, Marie-Françoise
Bessis, Didier
Caron, Olivier
Caux, Frédéric
Collignon, Patrick
Coupier, Isabelle
Cremin, Carol
Dollfus, Hélène
Dugast, Catherine
Escudier, Bernard
Faivre, Laurence
Field, Michel
Gilbert-Dussardier, Brigitte
Janin, Nicolas
Leport, Yves
Leroux, Dominique
Lipsker, Dan
Malthieu, Félicia
McGilliwray, Barbara
Maugard, Christine
Méjean, Arnaud
Mortemousque, Isabelle
Plessis, Ghislaine
Poppe, Bruce
Pruvost-Balland, Christelle
Rooker, Serena
Roume, Joelle
Soufir, Nadem
Steinraths, Michelle
Tan, Min-Han
Théodore, Christine
Thomas, Luc
Vabres, Pierre
Van Glabeke, Emmanuel
Meric, Jean-Baptiste
Verkarre, Virginie
Lenoir, Gilbert
Joulin, Virginie
Deveaux, Sophie
Cusin, Veronica
Feunteun, Jean
Teh, Bin Tean
Paillerets, Brigitte Bressac-de
Richard, Stéphane
… (more) - Abstract:
- Abstract : Background: Hereditary leiomyomatosis and renal cell cancer (HLRCC) is an autosomal dominant disorder predisposing humans to cutaneous and uterine leiomyomas; in 20% of affected families, type 2 papillary renal cell cancers (PRCCII) also occur with aggressive course and poor prognosis. HLRCC results from heterozygous germline mutations in the tumour suppressor fumarate hydratase ( FH ) gene. Methods: As part of the French National Cancer Institute (INCa) 'Inherited predispositions to kidney cancer' network, sequence analysis and a functional study of FH were preformed in 56 families with clinically proven or suspected HLRCC and in 23 patients with isolated PRCCII (5 familial and 18 sporadic). Results: The study identified 32 different germline FH mutations (15 missense, 6 frameshifts, 4 nonsense, 1 deletion/insertion, 5 splice site, and 1 complete deletion) in 40/56 (71.4%) families with proven or suspected HLRCC and in 4/23 (17.4%) probands with PRCCII alone, including 2 sporadic cases. 21 of these were novel and all were demonstrated as deleterious by significant reduction of FH enzymatic activity. In addition, 5 asymptomatic parents in 3 families were confirmed as carrying disease-causing mutations. Conclusions: This study identified and characterised 21 novel FH mutations and demonstrated that PRCCII can be the only one manifestation of HLRCC. Due to the incomplete penetrance of HLRCC, the authors propose to extend the FH mutation analysis to every patientAbstract : Background: Hereditary leiomyomatosis and renal cell cancer (HLRCC) is an autosomal dominant disorder predisposing humans to cutaneous and uterine leiomyomas; in 20% of affected families, type 2 papillary renal cell cancers (PRCCII) also occur with aggressive course and poor prognosis. HLRCC results from heterozygous germline mutations in the tumour suppressor fumarate hydratase ( FH ) gene. Methods: As part of the French National Cancer Institute (INCa) 'Inherited predispositions to kidney cancer' network, sequence analysis and a functional study of FH were preformed in 56 families with clinically proven or suspected HLRCC and in 23 patients with isolated PRCCII (5 familial and 18 sporadic). Results: The study identified 32 different germline FH mutations (15 missense, 6 frameshifts, 4 nonsense, 1 deletion/insertion, 5 splice site, and 1 complete deletion) in 40/56 (71.4%) families with proven or suspected HLRCC and in 4/23 (17.4%) probands with PRCCII alone, including 2 sporadic cases. 21 of these were novel and all were demonstrated as deleterious by significant reduction of FH enzymatic activity. In addition, 5 asymptomatic parents in 3 families were confirmed as carrying disease-causing mutations. Conclusions: This study identified and characterised 21 novel FH mutations and demonstrated that PRCCII can be the only one manifestation of HLRCC. Due to the incomplete penetrance of HLRCC, the authors propose to extend the FH mutation analysis to every patient with PRCCII occurring before 40 years of age or when renal tumour harbours characteristic histologic features, in order to discover previously ignored HLRCC affected families. … (more)
- Is Part Of:
- Journal of medical genetics. Volume 48:Issue 4(2011)
- Journal:
- Journal of medical genetics
- Issue:
- Volume 48:Issue 4(2011)
- Issue Display:
- Volume 48, Issue 4 (2011)
- Year:
- 2011
- Volume:
- 48
- Issue:
- 4
- Issue Sort Value:
- 2011-0048-0004-0000
- Page Start:
- 226
- Page End:
- 234
- Publication Date:
- 2011-03-12
- Subjects:
- Leiomyomatosis -- FH -- HLRCC -- papillary renal cell cancer type II -- genetics -- molecular genetics -- cancer -- urological
Medical genetics -- Periodicals
616.042 - Journal URLs:
- http://jmg.bmjjournals.com/ ↗
http://www.bmj.com/archive ↗ - DOI:
- 10.1136/jmg.2010.085068 ↗
- Languages:
- English
- ISSNs:
- 1468-6244
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 18218.xml